BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10753466)

  • 1. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex.
    Legraverend M; Tunnah P; Noble M; Ducrot P; Ludwig O; Grierson DS; Leost M; Meijer L; Endicott J
    J Med Chem; 2000 Apr; 43(7):1282-92. PubMed ID: 10753466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
    De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
    Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
    Arris CE; Boyle FT; Calvert AH; Curtin NJ; Endicott JA; Garman EF; Gibson AE; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Lawrie AM; Newell DR; Noble ME; Sausville EA; Schultz R; Yu W
    J Med Chem; 2000 Jul; 43(15):2797-804. PubMed ID: 10956187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.
    Otyepka M; Krystof V; Havlícek L; Siglerová V; Strnad M; Koca J
    J Med Chem; 2000 Jun; 43(13):2506-13. PubMed ID: 10891109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
    Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
    Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular model of cyclin-dependent kinase 5 complexed with roscovitine.
    Filgueira de Azevedo W; Gaspar RT; Canduri F; Camera JC; Freitas da Silveira NJ
    Biochem Biophys Res Commun; 2002 Oct; 297(5):1154-8. PubMed ID: 12372407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases.
    Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L
    Bioorg Med Chem Lett; 1998 Apr; 8(7):793-8. PubMed ID: 9871543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D-QSAR CoMFA on cyclin-dependent kinase inhibitors.
    Ducrot P; Legraverend M; Grierson DS
    J Med Chem; 2000 Nov; 43(22):4098-108. PubMed ID: 11063606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717.
    Dreyer MK; Borcherding DR; Dumont JA; Peet NP; Tsay JT; Wright PS; Bitonti AJ; Shen J; Kim SH
    J Med Chem; 2001 Feb; 44(4):524-30. PubMed ID: 11170642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.
    Mesguiche V; Parsons RJ; Arris CE; Bentley J; Boyle FT; Curtin NJ; Davies TG; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Jewsbury P; Johnson LN; Newell DR; Noble ME; Wang LZ; Hardcastle IR
    Bioorg Med Chem Lett; 2003 Jan; 13(2):217-22. PubMed ID: 12482427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological activities of C-2, N-9 substituted 6-benzylaminopurine derivatives as cyclin-dependent kinase inhibitor.
    Oh CH; Lee SC; Lee KS; Woo ER; Hong CY; Yang BS; Baek DJ; Cho JH
    Arch Pharm (Weinheim); 1999 Jun; 332(6):187-90. PubMed ID: 10399486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine.
    Schulze-Gahmen U; Brandsen J; Jones HD; Morgan DO; Meijer L; Vesely J; Kim SH
    Proteins; 1995 Aug; 22(4):378-91. PubMed ID: 7479711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
    Davies TG; Bentley J; Arris CE; Boyle FT; Curtin NJ; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Hardcastle IR; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Wang L; Whitfield HJ
    Nat Struct Biol; 2002 Oct; 9(10):745-9. PubMed ID: 12244298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
    Chang YT; Gray NS; Rosania GR; Sutherlin DP; Kwon S; Norman TC; Sarohia R; Leost M; Meijer L; Schultz PG
    Chem Biol; 1999 Jun; 6(6):361-75. PubMed ID: 10375538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design of potent CDK1 inhibitors derived from olomoucine.
    Furet P; Zimmermann J; Capraro HG; Meyer T; Imbach P
    J Comput Aided Mol Des; 2000 Jul; 14(5):403-9. PubMed ID: 10896313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.
    Gucký T; Jorda R; Zatloukal M; Bazgier V; Berka K; Řezníčková E; Béres T; Strnad M; Kryštof V
    J Med Chem; 2013 Aug; 56(15):6234-47. PubMed ID: 23829517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.
    Gray NS; Wodicka L; Thunnissen AM; Norman TC; Kwon S; Espinoza FH; Morgan DO; Barnes G; LeClerc S; Meijer L; Kim SH; Lockhart DJ; Schultz PG
    Science; 1998 Jul; 281(5376):533-8. PubMed ID: 9677190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The design and synthesis of purine inhibitors of CDK2. III.
    Shum PW; Peet NP; Weintraub PM; Le TB; Zhao Z; Barbone F; Cashman B; Tsay J; Dwyer S; Loos PC; Powers EA; Kropp K; Wright PS; Bitonti A; Dumont J; Borcherding DR
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1067-78. PubMed ID: 11562960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for chemical inhibition of CDK2.
    Kim SH; Schulze-Gahmen U; Brandsen J; de Azevedo Júnior WF
    Prog Cell Cycle Res; 1996; 2():137-45. PubMed ID: 9552391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.